SCHEMBL5085699

SCHEMBL5085699

C=CC(=O)OC(COc1ccccc1Br)COc1ccccc1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 3/20 0.41
KMT2A Q03164 8/20 0.41
MEN1 O00255 6/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
GAA P10253 2/20 0.41
ATM Q13315 1/20 0.41
RAB9A P51151 4/20 0.39
NPC1 O15118 3/20 0.39
POLB P06746 1/20 0.39
ALDH1A1 P00352 3/20 0.38
LIG1 P18858 1/20 0.38
LMNA P02545 4/20 0.38
KDM4E B2RXH2 2/20 0.38
HPGD P15428 2/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
THRB P10828 1/20 0.38
MAPT P10636 2/20 0.36
STAT3 P40763 1/20 0.36
STAT1 P42224 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19766706 0.82 LMNA (0.50) KMT2ASMN1; SMN2ATMPOLBALDH1A1
SCHEMBL1394646 0.80 KDM4E (0.51) KMT2AMEN1SMN1; SMN2ATMALDH1A1
SCHEMBL4191192 0.79 KDM4E (0.50) KMT2AMEN1SMN1; SMN2ATMALDH1A1
SCHEMBL4191519 0.79 HTT (0.47) KMT2AMEN1SMN1; SMN2GAARAB9A
SCHEMBL4194281 0.79 HTT (0.47) KMT2AMEN1SMN1; SMN2GAARAB9A
SCHEMBL5088322 0.78 THRB (0.57) KMT2AMEN1SMN1; SMN2GAARAB9A
SCHEMBL4188682 0.78 MAPT (0.44) SMN1; SMN2RAB9ANPC1ALDH1A1LMNA
SCHEMBL11512126 0.77 ADRB2 (0.43) SMN1; SMN2ALDH1A1LMNAKDM4EHTT
SCHEMBL11048017 0.77 SMN1; SMN2 (0.40) SMN1; SMN2ATMRAB9ANPC1ALDH1A1
SCHEMBL4195601 0.77 PTPN7 (0.44) KMT2AMEN1SMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492275-B2 Photo-curable compositions containing high refractive index monomers for use in 3D printing applications ARKEMA FRANCE (FR) 2025-12-09 US claimed
US-20240052081-A1 PHOTO-CURABLE COMPOSITIONS CONTAINING HIGH REFRACTIVE INDEX MONOMERS FOR USE IN 3D PRINTING APPLICATIONS ARKEMA FRANCE (FR) 2024-02-15 US claimed
EP-4028480-A1 PHOTO-CURABLE COMPOSITIONS CONTAINING HIGH REFRACTIVE INDEX MONOMERS FOR USE IN 3D PRINTING APPLICATIONS ARKEMA FRANCE (FR) 2022-07-20 EP claimed
US-20050049376-A1 High refractive index, uv-curable monomers and coating compositions prepared therefrom GENERAL ELECTRIC COMPANY 2005-03-03 US claimed
US-12492275-B2 Photo-curable compositions containing high refractive index monomers for use in 3D printing applications ARKEMA FRANCE (FR) 2025-12-09 US disclosed
US-20240052081-A1 PHOTO-CURABLE COMPOSITIONS CONTAINING HIGH REFRACTIVE INDEX MONOMERS FOR USE IN 3D PRINTING APPLICATIONS ARKEMA FRANCE (FR) 2024-02-15 US disclosed
EP-4028480-A1 PHOTO-CURABLE COMPOSITIONS CONTAINING HIGH REFRACTIVE INDEX MONOMERS FOR USE IN 3D PRINTING APPLICATIONS ARKEMA FRANCE (FR) 2022-07-20 EP disclosed
US-20080145545-A1 METAL OXIDE AND SULFUR-CONTAINING COATING COMPOSITIONS, METHODS OF USE, AND ARTICLES PREPARED THEREFROM CITIBANK, N.A., AS COLLATERAL AGENT 2008-06-19 US disclosed
US-7271283-B2 High refractive index, UV-curable monomers and coating compositions prepared therefrom GENERAL ELECTRIC COMPANY (US) 2007-09-18 US disclosed
EP-1512704-A1 High refractive index, UV-curable monomers and coating compositions prepared therefrom GENERAL ELECTRIC COMPANY (US) 2005-03-09 EP disclosed
US-20050049376-A1 High refractive index, uv-curable monomers and coating compositions prepared therefrom GENERAL ELECTRIC COMPANY 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049376-A1 High refractive index, uv-curable monomers and coating compositions prepared therefrom MACF1, WASF2, THEM6 GRM4 1048/4885KMT2A 2677/4885MEN1 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.